Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Research analysts at Wedbush reduced their Q1 2025 earnings estimates for shares of Bicara Therapeutics in a research note issued to investors on Thursday, March 27th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.40) for the quarter, down from their prior forecast of ($0.33). Wedbush has a “Outperform” rating and a $31.00 price target on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share. Wedbush also issued estimates for Bicara Therapeutics’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.67) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($1.87) EPS and FY2027 earnings at ($2.10) EPS.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.08).

BCAX has been the topic of several other reports. HC Wainwright increased their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, January 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $13.40 on Monday. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09. The business has a 50-day moving average of $13.04.

Hedge Funds Weigh In On Bicara Therapeutics

A number of large investors have recently made changes to their positions in the stock. California State Teachers Retirement System acquired a new stake in Bicara Therapeutics in the fourth quarter valued at $25,000. Spire Wealth Management acquired a new stake in Bicara Therapeutics in the 4th quarter valued at about $31,000. BNP Paribas Financial Markets acquired a new stake in Bicara Therapeutics in the 4th quarter valued at about $32,000. Legal & General Group Plc purchased a new position in Bicara Therapeutics during the 4th quarter valued at about $33,000. Finally, Summit Investment Advisors Inc. acquired a new position in Bicara Therapeutics during the fourth quarter worth about $35,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.